共同药业连亏1年半 2021上市中信证券保荐两募资共6亿

中金财经2025-10-21

中国经济网北京10月21日讯共同药业(300966.SZ) 2025年半年度报告显示，2025年上半年，公司实现营业收入3.02亿元，同比增长29.33%；归属于上市公司股东的净利润-1115.25万元，上年同期为-511.86万元；归属于上市公司股东的扣除非经常性损益的净利润-1021.91万元，上年同期为-492.68万元；经营活动产生的现金流量净额为-579.29万元，上年同期为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2577884153?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/ http://caiji.3g.cnfol.com/colect/202510/21/20251021441639.jpg?op=imageView2&mode=2&width=256&height=256&quality=70&format=png","is_english":false,"pubTime":"2025-10-21 15:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577884153","market":"us","top_or_hot":-1,"title":"共同药业连亏1年半 2021上市中信证券保荐两募资共6亿","media":"中金财经","content":"<div>\n<p>中国经济网北京10月21日讯 共同药业(300966.SZ) 2025年半年度报告显示，2025年上半年，公司实现营业收入3.02亿元，同比增长29.33%；归属于上市公司股东的净利润-1115.25万元，上年同期为-511.86万元；归属于上市公司股东的扣除非经常性损益的净利润-1021.91万元，上年同期为-492.68万元；经营活动产生的现金流量净额为-579.29万元，上年同期为...</p>\n\n<a href=\"http://sc.stock.cnfol.com/gushizhibo/20251021/31723491.shtml\">网页链接</a>\n\n</div>\n","source":"zhongjincaijing_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>共同药业连亏1年半 2021上市中信证券保荐两募资共6亿</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n共同药业连亏1年半 2021上市中信证券保荐两募资共6亿\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-21 15:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://sc.stock.cnfol.com/gushizhibo/20251021/31723491.shtml><strong>中金财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中国经济网北京10月21日讯 共同药业(300966.SZ) 2025年半年度报告显示，2025年上半年，公司实现营业收入3.02亿元，同比增长29.33%；归属于上市公司股东的净利润-1115.25万元，上年同期为-511.86万元；归属于上市公司股东的扣除非经常性损益的净利润-1021.91万元，上年同期为-492.68万元；经营活动产生的现金流量净额为-579.29万元，上年同期为...</p>\n\n<a href=\"http://sc.stock.cnfol.com/gushizhibo/20251021/31723491.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1521","symbol_name":"挪威政府全球养老基金持仓","start_time":0,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251021/31723491.shtml","article_id":"2577884153","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/ http://caiji.3g.cnfol.com/colect/202510/21/20251021441639.jpg?op=imageView2&mode=2&width=256&height=256&quality=70&format=png"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577884153","pubTimestamp":1761031026,"columns":[],"sourceInfo":{"source_id":"zhongjincaijing_highlight","name":"中金在线"},"weMediaInfo":null,"summary":"中国经济网北京10月21日讯 共同药业 2025年半年度报告显示，2025年上半年，公司实现营业收入3.02亿元，同比增长29.33%；归属于上市公司股东的净利润-1115.25万元，上年同期为-511.86万元；归属于上市公司股东的扣除非经常性损益的净利润-1021.91万元，上年同期为-492.68万元；经营活动产生的现金流量净额为-579.29万元，上年同期为3411.45万元。　　共同药业本次发行募集资金总额23,896.00万元；扣除发行费用后，募集资金净额为19,418.21万元。","collect":0,"end_time":0,"defaultTopTitle":"cnfol.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300966":"共同药业","600030":"中信证券","BK1521":"挪威政府全球养老基金持仓","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","BK0183":"MSCI概念","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","BK0188":"融资融券","BK0012":"证金概念","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK1564":"中资券商股","BK0028":"国家队","BK0276":"资本市场","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","06030":"中信证券","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK1516":"腾讯概念","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1997245177.USD":"安联神洲A股基金","LU1720050803.USD":"安联全方位中国股票基金","BK1147":"投资银行业与经纪业","BK0196":"行业龙头","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","BK0239":"医药制造"},"translate_title":"Common Pharmaceutical has suffered losses for one and a half consecutive years and went public in 2021. CITIC Securities sponsored two funds to raise a total of 600 million","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300966":1.5,"600030":1.5,"06030":1.5},"content_text":"中国经济网北京10月21日讯 共同药业(300966.SZ) 2025年半年度报告显示，2025年上半年，公司实现营业收入3.02亿元，同比增长29.33%；归属于上市公司股东的净利润-1115.25万元，上年同期为-511.86万元；归属于上市公司股东的扣除非经常性损益的净利润-1021.91万元，上年同期为-492.68万元；经营活动产生的现金流量净额为-579.29万元，上年同期为3411.45万元。\r\n\r\n　　    \r\n\r\n　　2024年，公司实现营业收入5.37亿元，同比下降5.26%；归属于上市公司股东的净利润-2759.11万元，上年同期为2300.50万元；归属于上市公司股东的扣除非经常性损益的净利润-2821.66万元，上年同期为2096.17万元；经营活动产生的现金流量净额-2058.84万元，上年同期为6813.25万元。\r\n\r\n　　2021年4月9日，共同药业在深交所创业板上市，公司本次公开发行股票的数量2,900万股，占发行后总股本的比例不低于25%，本次发行价格为8.24元/股。共同药业的保荐机构(主承销商)为中信证券股份有限公司，保荐代表人为彭浏用、周游。\r\n\r\n　　共同药业本次发行募集资金总额23,896.00万元；扣除发行费用后，募集资金净额为19,418.21万元。2021年4月2日，共同药业发布的创业板首次公开发行股票招股说明书显示，公司拟募集资金65,000.00万元，用于黄体酮及中间体BA生产建设项目、补充流动资金。\r\n\r\n　　共同药业公开发行新股的发行费用(不含增值税)合计4,477.79万元。其中，保荐及承销费用3,000.00万元。\r\n\r\n　　2022年12月13日，共同药业发布创业板向不特定对象发行可转换公司债券上市公告书。共同药业本次可转债的募集资金总额为人民币38,000.00万元，扣除发行费用(不含税)后的募集资金净额为37,322.31万元。公司募集资金净额拟投资于黄体酮及中间体BA生产建设项目、补充流动资金。共同药业表示，本次发行可转换公司债券募集资金扣除承销及保荐费用后的余额已由保荐机构(主承销商)于2022年12月2日汇入公司指定的募集资金账户。大信会计师事务所(特殊普通合伙)已对前述募集资金到账情况进行了验资，并出具了大信验字[2022]第5-00022号《验资报告》。\r\n\r\n　　经计算，上述两次募资金额合计为61896万元。\r\n\r\n　　\r\n\r\n　　【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2577884153","isCrawlerRequest":true}